Acamprosate (Brand name: Campral), with its CAS registry number of , has its IUPAC name of 3-acetamidopropane-1-sulfonic acid.

Following are the detailed information of Acamprosate:
1. Indication of Acamprosate: For the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation.
2. Pharmacodynamics of Acamprosate: Pharmacodynamic studies have shown that reduces alcohol intake in alcohol-dependent animals in a dose-dependent manner and that this effect appears to be specific to alcohol and the mechanisms of alcohol dependence. Acamprosate calcium has negligible observable central nervous system (CNS) activity in animals outside of its effects on alcohol dependence, exhibiting no anticonvulsant, antidepressant, or anxiolytic activity.
3. Mechanism of action: The mechanism of action of acamprosate in maintenance of alcohol abstinence is not completely understood. Chronic alcohol exposure is hypothesized to alter the normal balance between neuronal excitation and inhibition. in vitro and in vivo studies in animals have provided evidence to suggest acamprosate may interact with glutamate and GABA neurotransmitter systems centrally, and has led to the hypothesis that acamprosate restores this balance. It seems to inhibit NMDA receptors while activating GABA receptors.
4. Metabolism of Acamprosate: Acamprosate does not undergo metabolism.
5. Toxicity of Acamprosate: In all reported cases of acute overdosage with acamprosate (total reported doses of up to 56 grams of acamprosate calcium), the only symptom that could be reasonably associated with acamprosate was diarrhea.